- Page 1 and 2:
2010 Annual Report CIBERDEM Centro
- Page 4 and 5:
Letter from the Scientific Director
- Page 6 and 7:
Contents Prologue Research results
- Page 8 and 9:
Research results Publications In 20
- Page 10 and 11:
Project management Introduction The
- Page 12 and 13:
Training programme Introduction The
- Page 14 and 15:
Outreach activities CIBERDEM Fundra
- Page 16 and 17:
More about CIBERDEM The Centro de I
- Page 18 and 19:
Human Resources In 2010, CIBERDEM h
- Page 20 and 21:
Transversal projects Di@bet.es Stud
- Page 22 and 23:
Di@bet.es Study Introduction Attemp
- Page 24 and 25:
CIBERDEM Projects Introduction CIBE
- Page 26 and 27:
girls (girls born small for gestati
- Page 28 and 29:
Biobank Introduction and objectives
- Page 30 and 31:
Metabolomics Platform Introduction
- Page 33 and 34:
Area 1 Insulin signalling and resis
- Page 35 and 36:
Diabetes and cardiovascular Faculta
- Page 37 and 38:
Metabolomics Platform Universitat R
- Page 39 and 40:
Obesity, inflammation and insulin r
- Page 41 and 42:
Mechanisms of control of glucose an
- Page 43 and 44:
Metabolic engineering and diabetes
- Page 45 and 46:
Molecular mechanisms of insulin res
- Page 47 and 48:
Molecular characteristics, and acti
- Page 49 and 50:
Heterogenic and polygenic diseases.
- Page 51:
Principal Investigator: Antonio Zor
- Page 54 and 55:
The research activity of this area
- Page 56 and 57:
The cationic cluster of group IVA p
- Page 58 and 59:
agent that affects the enterohepati
- Page 60 and 61:
Dyslipidaemia, inflammation and end
- Page 62 and 63:
Daño orgánico en la diabetes mell
- Page 64 and 65:
Proteomic analysis of plasma in the
- Page 66 and 67:
Prenatal growth restriction and sub
- Page 68 and 69:
The effects of metformin on cardiov
- Page 70 and 71:
Lipids and Arteriosclerosis Researc
- Page 72 and 73:
Review Pitavastatin - from clinical
- Page 74 and 75:
Diabetobe Hospital Clínico San Car
- Page 76 and 77:
Scientific collaborations within CI
- Page 78 and 79:
Atherosclerosis, 209, 201-205 (2010
- Page 80 and 81: Solvay, SA: 2008-2010 Principal Inv
- Page 82 and 83: Endocrinology and Nutrition Service
- Page 84 and 85: Prevención de la Diabetes mellitus
- Page 86 and 87: Pharmacological targets in inflamma
- Page 88 and 89: Diabetes and Metabolic Associated D
- Page 90 and 91: Autonomous Community project Grup d
- Page 92 and 93: Area 3 of CIBERDEM comprises thirte
- Page 94 and 95: Escrivá F, Alvarez C J Mol Endocri
- Page 96 and 97: Am J Physiol Endocrinol Metab, 298,
- Page 98 and 99: Transgenic animal models and gene t
- Page 100 and 101: Ayuso E, Mingozzi F, Bosch F Curr G
- Page 102 and 103: Laboratory of Molecular Endocrinolo
- Page 104 and 105: Hospital de Cruces Diabetes Researc
- Page 106 and 107: Research grants International proje
- Page 108 and 109: Proinsulin and tyrosine hydroxilase
- Page 110 and 111: Genomic programming of beta cells I
- Page 112 and 113: Diabetes and obesity: biopathology
- Page 114 and 115: Utilidad de la ecografía arterial
- Page 116 and 117: Islet cell and stem cell physiology
- Page 118 and 119: in diabetic patients with chronic c
- Page 120 and 121: Liraglutide versus sitagliptin for
- Page 122 and 123: Unit of Cell Physiology and Nutriti
- Page 124 and 125: National projects Efectos a corto y
- Page 126 and 127: Altirriba J, Gasa R, Casas S, Ramí
- Page 128 and 129: Transcriptional mechanisms of pancr
- Page 132 and 133: Principal Investigator index Álvar
- Page 134 and 135: Publications index* A map of open c
- Page 136 and 137: dDOR is an EcR coactivator that for
- Page 138 and 139: Morales-Suárez-Varela MM, Mansego
- Page 140 and 141: Obesity and insulin resistance-rela
- Page 142 and 143: Reduced insulin secretion in protei
- Page 144 and 145: Treatment of polycystic ovary syndr
- Page 146: CIBERDEM, the Spanish Biomedical Re